BRPI0513081A - método para modular a expressão gênica pela alteração do conteúdo de cpg, sistema de expressão, medicamento que o compreende e respectivos usos - Google Patents

método para modular a expressão gênica pela alteração do conteúdo de cpg, sistema de expressão, medicamento que o compreende e respectivos usos

Info

Publication number
BRPI0513081A
BRPI0513081A BRPI0513081-6A BRPI0513081A BRPI0513081A BR PI0513081 A BRPI0513081 A BR PI0513081A BR PI0513081 A BRPI0513081 A BR PI0513081A BR PI0513081 A BRPI0513081 A BR PI0513081A
Authority
BR
Brazil
Prior art keywords
expression
altering
drug
gene expression
modulate gene
Prior art date
Application number
BRPI0513081-6A
Other languages
English (en)
Inventor
Frank Notka
Marcus Graf
Doris Leikam
Ralf Wagner
David Raab
Original Assignee
Geneart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35839637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0513081(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102004037611A external-priority patent/DE102004037611B4/de
Priority claimed from DE200410037652 external-priority patent/DE102004037652B4/de
Application filed by Geneart Ag filed Critical Geneart Ag
Publication of BRPI0513081A publication Critical patent/BRPI0513081A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Control Of Electric Motors In General (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Electrotherapy Devices (AREA)

Abstract

MéTODO PARA MODULAR A EXPRESSãO GêNICA PELA ALTERAçãO DO CONTEúDO DE CPG, SISTEMA DE EX-PRESSãO, MEDICAMENTO QUE O COMPREENDE E RESPECTIVOS USOS. A presente invenção refere-se a modificações de ácido nucléico para uma modulação direcionada da expressão pela inserção ou remoção selecionada de binucleotídeos CpG. A invenção também refere-se a ácidos nucléicos modificados e vetores de expressão.
BRPI0513081-6A 2004-08-03 2005-08-03 método para modular a expressão gênica pela alteração do conteúdo de cpg, sistema de expressão, medicamento que o compreende e respectivos usos BRPI0513081A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004037611A DE102004037611B4 (de) 2004-08-03 2004-08-03 Induzierbare Genexpression
DE200410037652 DE102004037652B4 (de) 2004-08-03 2004-08-03 Verfahren zur Modulation der Genexpression durch Änderung des CpG Gehalts
PCT/EP2005/008423 WO2006015789A2 (de) 2004-08-03 2005-08-03 Verfahren zur modulation der genexpression durch änderung des cpg gehalts

Publications (1)

Publication Number Publication Date
BRPI0513081A true BRPI0513081A (pt) 2008-04-22

Family

ID=35839637

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513081-6A BRPI0513081A (pt) 2004-08-03 2005-08-03 método para modular a expressão gênica pela alteração do conteúdo de cpg, sistema de expressão, medicamento que o compreende e respectivos usos

Country Status (13)

Country Link
US (4) US8859275B2 (pt)
EP (1) EP1776460B8 (pt)
JP (1) JP4550115B2 (pt)
KR (1) KR101222628B1 (pt)
AT (1) ATE453716T1 (pt)
AU (1) AU2005270430B2 (pt)
BR (1) BRPI0513081A (pt)
CA (1) CA2575490A1 (pt)
DE (1) DE502005008794D1 (pt)
DK (1) DK1776460T3 (pt)
IL (1) IL180786A (pt)
MX (1) MX2007001292A (pt)
WO (1) WO2006015789A2 (pt)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015789A2 (de) * 2004-08-03 2006-02-16 Geneart Ag Verfahren zur modulation der genexpression durch änderung des cpg gehalts
EP2366787B1 (en) 2006-01-13 2019-12-11 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
WO2008069663A1 (en) 2006-12-07 2008-06-12 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum Use of a varicellovirus tap-inhibitor for the induction of tumor- or virus-specific immunity against teipp
EP2068925A4 (en) 2007-05-07 2011-08-31 Medimmune Llc ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
EP2019134A1 (en) * 2007-07-26 2009-01-28 Vision 7 GmbH Gene therapy of chronic granulomatous disease
SI3093345T1 (sl) 2007-07-26 2019-08-30 Uniqure Ip B.V. Bakulovirusni vektorji, ki vsebujejo ponavljajoča kodirna zaporedja z različnimi kodonskimi preferencami
ES2429142T3 (es) 2009-01-30 2013-11-13 Uniqure Ip B.V. Agentes terapéuticos de alanina-glioxilato aminotransferasa
US20160186188A1 (en) * 2010-02-09 2016-06-30 Rutgers, The State University Of New Jersey Methods for altering polypeptide expression and solubility
US9970874B2 (en) 2010-11-29 2018-05-15 Dako Denmark A/S Methods and systems for analyzing images of specimens processed by a programmable quantitative assay
DE102010056289A1 (de) 2010-12-24 2012-06-28 Geneart Ag Verfahren zur Herstellung von Leseraster-korrekten Fragment-Bibliotheken
US20150120265A1 (en) 2011-09-01 2015-04-30 Genome Compiler Corporation System for polynucleotide construct design, visualization and transactions to manufacture the same
CN103945931B (zh) 2011-09-26 2017-03-22 基因技术股份公司 高效的小体积核酸合成
US12595500B2 (en) 2011-09-26 2026-04-07 Life Technologies Corporation High efficiency, small volume nucleic acid synthesis
WO2014153188A2 (en) 2013-03-14 2014-09-25 Life Technologies Corporation High efficiency, small volume nucleic acid synthesis
WO2013152220A2 (en) 2012-04-04 2013-10-10 Life Technologies Corporation Tal-effector assembly platform, customized services, kits and assays
TWI707038B (zh) 2013-08-05 2020-10-11 美商扭轉生物科技有限公司 重新合成之基因庫
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
EP4043032A1 (en) * 2013-08-21 2022-08-17 CureVac AG Rabies vaccine
DK3035955T3 (da) * 2013-08-21 2019-12-02 Curevac Ag Sammensætning og vaccine til behandling af lungekræft
EP3035955B1 (en) * 2013-08-21 2019-09-11 CureVac AG Composition and vaccine for treating lung cancer
EP3586871A3 (en) * 2013-08-21 2020-03-11 CureVac AG Respiratory syncytial virus (rsv) vaccine
BR112016001192A2 (pt) 2013-08-21 2017-08-29 Curevac Ag Vacina contra a raiva
WO2015024664A1 (en) * 2013-08-21 2015-02-26 Curevac Gmbh Composition and vaccine for treating prostate cancer
WO2016077123A1 (en) 2014-11-10 2016-05-19 Moderna Therapeutics, Inc. Multiparametric nucleic acid optimization
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
US10407676B2 (en) 2014-12-09 2019-09-10 Life Technologies Corporation High efficiency, small volume nucleic acid synthesis
WO2016126882A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
DK3294885T3 (da) 2015-05-08 2020-08-10 Curevac Real Estate Gmbh Fremgangsmåde til at fremstille rna
PL4108769T3 (pl) 2015-05-29 2024-02-05 CureVac Manufacturing GmbH Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym
KR20180050411A (ko) 2015-09-18 2018-05-14 트위스트 바이오사이언스 코포레이션 올리고핵산 변이체 라이브러리 및 그의 합성
KR102794025B1 (ko) 2015-09-22 2025-04-09 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
CN115920796A (zh) 2015-12-01 2023-04-07 特韦斯特生物科学公司 功能化表面及其制备
JP6854340B2 (ja) 2016-08-22 2021-04-07 ツイスト バイオサイエンス コーポレーション デノボ合成された核酸ライブラリ
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
EP3538549A1 (en) 2016-11-10 2019-09-18 iOmx Therapeutics AG Or10h1 antigen binding proteins and uses thereof
KR102514213B1 (ko) 2016-12-16 2023-03-27 트위스트 바이오사이언스 코포레이션 면역 시냅스의 변이체 라이브러리 및 그의 합성
CN110892485B (zh) 2017-02-22 2024-03-22 特韦斯特生物科学公司 基于核酸的数据存储
WO2018170169A1 (en) 2017-03-15 2018-09-20 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
WO2018195339A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
US10696965B2 (en) 2017-06-12 2020-06-30 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
CN111566125A (zh) 2017-09-11 2020-08-21 特韦斯特生物科学公司 Gpcr结合蛋白及其合成
CN111565834B (zh) 2017-10-20 2022-08-26 特韦斯特生物科学公司 用于多核苷酸合成的加热的纳米孔
KR102804057B1 (ko) 2018-01-04 2025-05-07 트위스트 바이오사이언스 코포레이션 Dna 기반 디지털 정보 저장
EP3508499A1 (en) 2018-01-08 2019-07-10 iOmx Therapeutics AG Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
EP3768858A1 (en) 2018-03-19 2021-01-27 Modernatx, Inc. Assembly and error reduction of synthetic genes from oligonucleotides
CA3100739A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
US12357959B2 (en) 2018-12-26 2025-07-15 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
CN113766930B (zh) 2019-02-26 2025-07-22 特韦斯特生物科学公司 Glp1受体的变异核酸文库
CA3131691A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
CN114040979B (zh) 2019-06-21 2024-06-28 国立大学法人大阪大学 稳定地保持外源基因的人工重组rna病毒的制作方法
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
WO2021003195A1 (en) * 2019-06-30 2021-01-07 John Fraser Wright Recombinant aav vectors with altered immunogencity and methods of making the same
CA3146023A1 (en) 2019-07-05 2021-01-14 Iomx Therapeutics Ag Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
JP2022548309A (ja) 2019-09-23 2022-11-17 ツイスト バイオサイエンス コーポレーション Ｃｒｔｈ２のバリアント核酸ライブラリー
WO2021061842A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for single domain antibodies
EP3822288A1 (en) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
IL293670A (en) 2019-12-09 2022-08-01 Twist Bioscience Corp Variable nucleic acid libraries for adenosine receptors
EP4175668A1 (en) 2020-07-06 2023-05-10 iOmx Therapeutics AG Antibodies binding igv of igsf11 (vsig3) and uses thereof
JP7842082B2 (ja) * 2020-07-21 2026-04-07 エフティージェン コーポレーション 眼疾患を処置するための組成物および方法
KR20230098317A (ko) 2020-11-03 2023-07-03 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 표적 세포가 제한되는, 공동자극, 이중특이적 및 2가 항-cd28 항체
EP3992205A1 (en) 2020-11-03 2022-05-04 Rheinische Friedrich-Wilhelms-Universität Bonn Sars coronavirus-2 spike protein binding compounds
WO2022106205A1 (en) 2020-11-18 2022-05-27 Rheinische Friedrich-Wilhelms-Universität Bonn Corona virus spike protein binding compounds
US20240174768A1 (en) 2021-03-03 2024-05-30 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Bispecific antibodies enhancing cell mediated immune responses
KR20240095165A (ko) * 2021-08-11 2024-06-25 솔리드 바이오사이언시즈 인크. 근이영양증의 치료
CN118077011A (zh) * 2022-09-30 2024-05-24 南京金斯瑞生物科技有限公司 一种降低外源核酸免疫原性的密码子优化
EP4491230A1 (en) 2023-07-14 2025-01-15 iOmx Therapeutics AG Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
CN120548326A (zh) 2022-12-23 2025-08-26 艾奥麦克斯治疗公司 靶向白细胞免疫球蛋白样受体亚家族b1（lilrb1）和lilrb2的交叉特异性抗原结合蛋白（abp）、其组合和用途
WO2026003224A2 (en) 2024-06-26 2026-01-02 Iomx Therapeutics Ag Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050131267A1 (en) * 1995-06-07 2005-06-16 Talmadge Karen D. System and method for delivering a therapeutic agent for bone disease
AU7690898A (en) * 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
SK287400B6 (sk) * 1999-09-25 2010-08-09 University Of Iowa Research Foundation Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
CA2403327C (en) 2000-03-15 2012-05-29 Prolume, Ltd. Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
ATE318908T1 (de) * 2000-05-18 2006-03-15 Geneart Gmbh Synthetische gene für gagpol und deren verwendungen
US6919204B2 (en) * 2000-09-29 2005-07-19 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
DE10053781B4 (de) 2000-10-30 2008-07-03 Geneart Ag Kernexportreportersystem
EP2224010B1 (en) 2001-04-05 2012-06-20 EMD Millipore Corporation Improved gene expression
WO2002099105A2 (en) 2001-06-05 2002-12-12 Cellectis Methods for modifying the cpg content of polynucleotides
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
DE60336736D1 (de) * 2002-07-16 2011-05-26 VGX Pharmaceuticals LLC Codon-optimierte synthetische plasmide
DE10260805A1 (de) * 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
WO2005114106A1 (en) 2004-05-12 2005-12-01 Northrop Grumman Corporation System and method for aligning multiple navignation components
WO2006015789A2 (de) 2004-08-03 2006-02-16 Geneart Ag Verfahren zur modulation der genexpression durch änderung des cpg gehalts
DE102004037611B4 (de) * 2004-08-03 2013-10-02 Geneart Ag Induzierbare Genexpression
DE102007052344B3 (de) * 2007-11-02 2009-03-12 Geneart Ag Selektion kodierender Nukleinsäure-Konstrukte auf Abwesenheit von Frameshift-Mutationen
US20160040163A1 (en) * 2013-03-15 2016-02-11 Pronai Therapeutics, Inc. Dnai for the modulation of genes

Also Published As

Publication number Publication date
AU2005270430A1 (en) 2006-02-16
IL180786A0 (en) 2007-06-03
KR101222628B1 (ko) 2013-01-16
JP4550115B2 (ja) 2010-09-22
JP2008507986A (ja) 2008-03-21
US8859275B2 (en) 2014-10-14
US10273486B2 (en) 2019-04-30
AU2005270430B2 (en) 2008-06-12
DK1776460T3 (da) 2010-04-12
DE502005008794D1 (de) 2010-02-11
EP1776460A2 (de) 2007-04-25
EP1776460B1 (de) 2009-12-30
WO2006015789A2 (de) 2006-02-16
HK1100089A1 (zh) 2007-09-07
US20210155940A1 (en) 2021-05-27
US20190270999A1 (en) 2019-09-05
CA2575490A1 (en) 2006-02-16
ATE453716T1 (de) 2010-01-15
MX2007001292A (es) 2007-07-04
EP1776460B2 (de) 2013-12-25
US20090324546A1 (en) 2009-12-31
IL180786A (en) 2013-08-29
US20150104832A1 (en) 2015-04-16
WO2006015789A3 (de) 2006-06-01
EP1776460B8 (de) 2014-02-26
KR20070041605A (ko) 2007-04-18

Similar Documents

Publication Publication Date Title
BRPI0513081A (pt) método para modular a expressão gênica pela alteração do conteúdo de cpg, sistema de expressão, medicamento que o compreende e respectivos usos
BR112015003947A2 (pt) proteínas de fusão e métodos para tratar, prevenir ou melhorar dor
GB2397818A (en) Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
MX2009003729A (es) Copuestos antagonistas de acido ribonucleico para la modulacion de proproteina convertasa subtilisina/kexina tipo 9a.
BRPI0917626A2 (pt) Método para modular atividade do fator 1 de transcrição do choque térmico (hsf1) em uma célula, método para aumentar ou diminuir a atividade de hsf1 em um indivíduo necessitando do mesmo método para tratar um paciente, método para identificar um agente que modula a atividade de hsf1 em uma célula, método para ativar a resposta ao choque térmico em uma célula ou em um paciente necessitando do mesmo e composição farmacêutica
ATE512222T1 (de) Modulation der expression von diacylglycerin- acyltransferase 2
BRPI0503857A (pt) sistemas e métodos de circuito de driver de coluna escalonada
BRPI0508931A (pt) ácido nucleico isolado, composição farmacêutica e usos de uma quantidade eficaz de um primeiro ligante de ácido nucleico
WO2005000201A3 (en) Modulation of apolipoprotein (a) expression
BRPI0516327A (pt) sistemas de policetìdeo sintase de pufa e usos dos mesmos
WO2004093783A3 (en) Modulation of apolipoprotein c-iii expression
WO2004044181A3 (en) Antisense modulation of apolipoprotein b expression
DE502007006037D1 (de) Multimer zur immunstimulation
WO2009076321A3 (en) Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides
MX2007008065A (es) Composiciones y metodos para modular la expresion genica usando oligonucleotidos autoprotegidos.
WO2003097662A8 (en) Antisense modulation of apolipoprotein b expression
WO2014066915A3 (en) Methods and compositions to produce ss-rnai activity with enhanced potency
WO2003014306A3 (en) Antisense modulation of cholesteryl ester transfer protein expression
WO2004055162A3 (en) Modulation of endothelial lipase expression
WO2005042552A3 (en) Modulation of sglt2 expression
EA201000769A1 (ru) Катенированные молекулы и содержащие их композиции для иммуностимуляции
WO2001083513A3 (en) Antisense modulation of inhibitor of dna binding-1 expression
BRPI0511761A (pt) método e sistema para solubilização de proteìna
WO2005021727A3 (en) Isoform-specific targeting of splice variants
WO2003027229A3 (en) Antisense modulation of rip2 expression

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.